Data Integrity - Requirements for a GMP-compliant Data Life Cycle

Data Integrity - Requirements for a GMP-compliant Data Life Cycle

Berlin, Germany

Course No 16275

You can find all other dates of this seminar in this overview.

Costs

Non-ECA Members: EUR 1990,--
ECA Members: EUR 1790,--
EU GMP Inspectorates: EUR 995,--
APIC Members: EUR 1890,--

(All prices excl. VAT)

If you have any questions, please contact us:
Tel.: +49 (0)6221 / 84 44 0 E-Mail: info@gmp-compliance.org

Speakers

Bob McDowall, R.D.McDowall Ltd.

Karl-Heinz Menges, Regierungspräsidium Darmstadt

Yves Samson, Kereon AG

Objectives

  • Understand the current FDA and EU GMP regulations and guidance impacting data integrity from paper records to hybrid and electronic systems.
  • Understand the FDA requirements for data integrity, MHRA Data Integrity guidance July 2016 and WHO guidance from September 2015.
  • Learn what is required for a data governance system from senior management through to staff in laboratories, manufacturing and quality assurance.
  • Understand the data life cycle and how it is linked with the business process and where problems can occur for both paper records, hybrid systems and electronic systems.

Background

Data Integrity is a global problem and currently a major concern with FDA and European Regulatory Agencies. Multiple FDA warning letters and EU GMP non-compliance reports have highlighted major data integrity failures and falsification in companies globally. The regulatory concern has been responded by the FDA issuing Compliance Program Guide that covers Pre-Approval Inspections. This document became effective in May 2012. The CPG objective 3 covers the laboratory data integrity audit. Furthermore in August 2014, the FDA issued Level 2 guidance on their web site about the sharing of login credentials for computerized systems and the use of test injections for testing into compliance.

In Europe, the UK’s MHRA issued two versions of a Guidance for Industry on Data Integrity in January and March 2015. This document outlines a data integrity governance system and principles for defining quality and data integrity into processes and systems. In addition, the guidance defines 19 terms and provides expectations and examples for many of them and therein is where the document’s value lies. A new draft version of the Guidance was published in July 2016. The WHO guidance is complimentary to the MHRA guidance in that it provides guidance for data governance and also expectations for records in both paper and electronic form.

As the regulators are tightening their inspection approaches it is important that managers, supervisors and users in regulated GMP laboratories understand the issues around data integrity and begin programs to ensure that their processes and systems ensure data integrity.

Target Group

  • Managers and staff from Manufacturing, QC/QA and Analytical Development Laboratories of pharmaceutical companies
  • CRO and CMO manufacturing, laboratory and QA personnel
  • Auditors (internal and external) responsible for performing self-inspections or external audits and needing to understand and assess data integrity

Programme

Why is Data Integrity Important? – Setting the Scene

  • Summary of falsification observed by FDA and EU inspectors 2005 – to date
  • FDAISA act 2012 and October 2014 Guidance for Industry and the impact on inspections
  • Inspection of computerised systems is changing: from paper to on-line
  • MHRA expectation for data governance; data integrity guidance documents 2015
  • FDA Level 2 guidance on data integrity: 2010 and 2014 postings
  • Impact of WHO guidance for data integrity
Data Integrity – EU GMP Requirements
  • EU GMP Chapter 4 – documentation
  • EU GMP Annex 11 computerised systems
  • Data integrity definitions
  • Difference between paper and electronic systems
Principles of Data Integrity
  • The ALCOA+ criteria for data integrity
  • Data life cycle in the process workflow – managing controls
  • Paper versus hybrid versus electronic systems
  • Validation of computerised systems for data integrity controls
  • Scope: production information versus laboratory data: why are laboratory data higher risk?
WHO and MHRA Data Integrity Guidances - Key Points
  • Data Governance System within the Pharmaceutical Quality System
  • Data Life Cycle
  • Spectrum of Systems: Paper to Electronic Systems with data integrity audit
FDA Draft Guidance for Industry ‘Data Integrity and Compliance with cGMP’
  • Background
  • Questions and Answers regarding Data Integrity
Role of Management in Data Integrity
  • Role of Senior, Production and Department Management in ensuring data integrity within an organisation and its suppliers
  • Data governance within a Quality System
  • Failures to address poor data integrity practices and no training
Development and Scope of a Data Governance System
  • Within a PQS, what is the scope of a data governance system?
  • Who are involved?
  • What are their roles?
Implementing Data Integrity Training
  • Scope of data integrity training
  • What cover in the training?
  • Checking training effectiveness
  • Integrating data integrity training with GMP training
US 21 CFR 211 and EU GMP Chapter 4: Complete data vs raw data vs primary record
  • Why complete data and raw data are important for understanding data integrity
  • EU GMP Chapter 4 requirements for raw data
  • 21 CFR 211 requirements for laboratory records: complete data
  • FDA Level 2 guidance: paper versus e-records
  • Complete data / raw data / primary record example
Case study: Data Integrity questions as part of an inspection
  • Lab System
  • QA System
  • Manufacturing System
Ensuring Data Integrity in a Chromatography System
  • Configuration of CDS software
  • SOP for integration
  • Using samples for testing the System
Audit Trails and their Review
  • Understanding Annex 11 requirements for audit trails
  • Differences between Part 11 and Annex 11 requirements for audit trail
  • Default comments versus free text as reasons for change
  • Review of audit trail entries: how to comply with Annex 11
  • Reality v regulation: are audit trails in commercial products ready for Annex 11?
  • User Account Management and Application
  • Configuration
  • Separation of roles and responsibilities between IT and the business
  • Documentation of the configuration of an application e.g. audit trail, user types and access privileges
  • User account management: the do’s and don’ts
  • User identities must be unique
  • Regular review of each system users and privileges
IT Support for Data Integrity
  • IT facilities, environmental controls and physical security
  • Qualified IT infrastructure and validated IT systems
  • Backup and recovery / Change control
  • IT support including database administration
  • Impact of IT infrastructure on data integrity
GMP meets the Cloud
  • Regulatory compliance requirements to consider before going to the cloud
  • Are ISO 27001 or SSAE 16 adequate to meet GMP regulations?
  • Whose responsibility is data integrity when using the cloud?
  • Cloud suppliers: are you dealing with a single entity?
  • How to select a cloud supplier
Case study: Can Spreadsheets meet Data Integrity requirements?
  • Problems with spreadsheets
  • Good Practice for using spreadsheets in a regulated environment
  • Building data integrity features into a spreadsheet
Supply Chain Data Integrity
  • Approaches to ensuring data integrity of your suppliers
  • Role of technical agreements and audits
Key Learning Points and Final Discussion
  • Summary of Data Integrity Requirements and Key Learning Points
  • Final Discussions and close of the course
Facilitated Discussion / Workshop on Key Data Integrity Topics
  • Recording results on paper
  • Configuration of software applications
  • Unique user identities for all users
  • Unauthorised access
  • Appropriate access privileges for each user role
  • Is my chromatographic system ready? Role of “test” injections
  • Audit trails – options for older systems
  • Manual chromatographic integration
  • Standalone versus network systems
  • Protecting electronic records of standalone systems
Workshop: Analysis of an FDA Warning Letter
  • Working in teams, attendees will analyse one of several FDA warning letters to identify key areas of regulatory concern
  • Group discussion of regulatory concerns identified
Workshop: Assessing a System for Data Integrity
  • Using a checklist based on the data integrity criteria, attendees will assess a system for data integrity

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK